Laipeng Liu, Pingfeng Zhang, Sheng Sun, Chuanpei Cao, Zhi Song
{"title":"Downregulation of microRNA-129-2 by Hepatitis B Virus Promotes Cell Proliferation in Hepatocellular Carcinoma.","authors":"Laipeng Liu, Pingfeng Zhang, Sheng Sun, Chuanpei Cao, Zhi Song","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>MicroRNA-192-2 has been shown to have a role in the early diagnosis of hepatocellular carcinoma (HCC), but the relationship between microRNA-192-2 and hepatitis B virus (HBV) in HCC patients remains unclear.</p><p><strong>Methods: </strong>Specimens were collected from 56 HCC patients diagnosed with HBV infection and 56 HCC patients without viral infection. HBV and miR-129-2 levels in HCC tissues, adjacent tissues, and cell lines were analyzed by RT‒PCR. miR-129-2 mimics were transfected to induce the overexpression of miR-129-2 and cell function was assessed by a wound healing test. Tumor formation experiments in nude mice were conducted to validate tumor proliferation.</p><p><strong>Results: </strong>In HCC patients, miR-192-2 was significantly downregulated in tumor tissues compared to adjacent tissues. Notably, miR-192-2 level was even lower in HCC patients with HBV-infection than those without the viral infection. Moreover, there was a negative correlation between miR-192-2 and HBV levels. Regardless of HBV infection, patients with low miR-192-2 levels had poorer prognosis than those with high miR-192-2 levels. HBV infection suppressed miR-192-2 expression in HCC cell lines. Furthermore, overexpression of miR-192-2 significantly inhibited cell proliferation both <i>in vitro</i> and <i>in vivo</i> in the HBV-infected group.</p><p><strong>Conclusion: </strong>Our study revealed that the expression of miR-192-2, a crucial tumor suppressor gene, was suppressed by the presence of HBV.</p>","PeriodicalId":8228,"journal":{"name":"Annals of clinical and laboratory science","volume":"54 5","pages":"643-651"},"PeriodicalIF":1.1000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of clinical and laboratory science","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: MicroRNA-192-2 has been shown to have a role in the early diagnosis of hepatocellular carcinoma (HCC), but the relationship between microRNA-192-2 and hepatitis B virus (HBV) in HCC patients remains unclear.
Methods: Specimens were collected from 56 HCC patients diagnosed with HBV infection and 56 HCC patients without viral infection. HBV and miR-129-2 levels in HCC tissues, adjacent tissues, and cell lines were analyzed by RT‒PCR. miR-129-2 mimics were transfected to induce the overexpression of miR-129-2 and cell function was assessed by a wound healing test. Tumor formation experiments in nude mice were conducted to validate tumor proliferation.
Results: In HCC patients, miR-192-2 was significantly downregulated in tumor tissues compared to adjacent tissues. Notably, miR-192-2 level was even lower in HCC patients with HBV-infection than those without the viral infection. Moreover, there was a negative correlation between miR-192-2 and HBV levels. Regardless of HBV infection, patients with low miR-192-2 levels had poorer prognosis than those with high miR-192-2 levels. HBV infection suppressed miR-192-2 expression in HCC cell lines. Furthermore, overexpression of miR-192-2 significantly inhibited cell proliferation both in vitro and in vivo in the HBV-infected group.
Conclusion: Our study revealed that the expression of miR-192-2, a crucial tumor suppressor gene, was suppressed by the presence of HBV.
期刊介绍:
The Annals of Clinical & Laboratory Science
welcomes manuscripts that report research in clinical
science, including pathology, clinical chemistry,
biotechnology, molecular biology, cytogenetics,
microbiology, immunology, hematology, transfusion
medicine, organ and tissue transplantation, therapeutics, toxicology, and clinical informatics.